Bionomics Limited (ASX:BNO, ADR:BMICY) is likely to trade higher after positive results from Phase I clinical trials of its ovarian cancer treatment drug.
After completing enrolment of 15 patients for the Phase I portion of the trial during 2013, data to date has found 10 of the patients have achieved a positive response.
The patients were treated with 12mg/m2 BNC105 in combination with the current standard therapy of carboplatin and gemcitabine.
Biomarker analysis of blood samples from patients taken within four hours of administration demonstrated that the 12mg/m2 dose induced a pharmacodynamic response indicative of BNC105 activity.
The same biomarkers have been observed in association with BNC105 activity in previous clinical trials.
One patient has completed the complete 12 cycles of treatment, which is comprised of six cycles of combination therapy and six cycles of BNC105 monotherapy.
This patient has experienced clinical benefit and has continued on BNC105 monotherapy since.
Ovarian cancer is the fifth leading cause of cancer-related deaths in women, and the market for drugs to treat ovarian cancer is valued at over $2 billion per annum.
The majority of patients relapse after surgery, demonstrating a clear unmet need for effective treatments.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.